Clinical trials: glp1 Agonist
Diabetes Mellitus, Diabetes Mellitus, Type 2
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
Glucagon-like peptide 1 (GLP-1) based therapies, such as exenatide, are already successfully employed in the treatment of Type 2 Diabetes (T2DM).
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity
- Trial name
- Braini-Ex (NCT01281228)
- Testing
- exenatide, exenatide + exendin (9-39)
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Type 2 Diabetes
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1 and GIP.
- Trial name
- NCT01043445
- Testing
- GPR 119 agonist, 2-oleyl glycerol, Oleic acid, Vehicle
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hyperlipidemia
Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans
Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to speculate whether exenatide affects hepatic lipoprotein production in humans since there is currently no evidence from animal models or in…
- Trial name
- NCT01056549
- Testing
- exenatide
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Muscle Mass
Strength Training Response of Muscle in GLP-1 Users
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function.
- Trial name
- STRONG-GLP (NCT07104539)
- Testing
- Strength Training, Wait first, then strength training
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Virginia Polytechnic Institute and State University
Sarcopenia
Creatine Supplementation During GLP-1a Therapy
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of…
- Trial name
- NCT07625202
- Testing
- Dietary supplementation during a 12 week resistance-training program (creatine)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Healthy, Hepatic Insufficiency
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to…
- Trial name
- NCT05882032
- Testing
- LY3502970
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alopecia
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use
A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days.
- Trial name
- GLP-1 (NCT07783113)
- Testing
- Dietary Supplement for Hair Loss
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Farmoquimica S.A.
Type 2 Diabetes Mellitus, Congestive Heart Failure
Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure
The purpose of this study is to determine if exenatide will improve global cardiac function in patients with type 2 diabetes mellitus and congestive heart failure, by favorable effects on cardiac metabolism leading to improvement…
- Trial name
- NCT00766857
- Testing
- exenatide, Insulin glargine
- Where
- Netherlands
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Obesity
Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet
Introduction: The success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss…
- Trial name
- S-LITE (NCT04122716)
- Testing
- Liraglutide, Exercise
- Where
- Denmark
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Obesity, Overweight
FutureShape Family
The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor…
- Trial name
- NCT07872904
- Testing
- Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector)
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Endocrinology, Diabetes, Type II
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable…
- Conditions
- Endocrinology, Diabetes, Type II, Obesity
- Trial name
- ARAY (NCT06851858)
- Testing
- AZD6234
- Where
- 18 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
GLP-1 Concentration
Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1
Determine if consuming a high protein nutrition shake reduces gastrointestinal symptoms associated with semaglutide injections.
- Trial name
- NCT07096739
- Testing
- High protein shake
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kate Farms Inc
Type 2 Diabetes
Pharmacogenomics of GLP1 Receptor Agonists
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility.
- Trial name
- NCT05762744
- Testing
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic…
- Trial name
- NCT07550634
- Testing
- MDR-001
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Obesity
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese…
- Trial name
- NCT07223216
- Testing
- BMF-650
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Biomea Fusion Inc.
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
GLP-1, Alcohol
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
- Trial name
- TAP (NCT07758231)
- Testing
- Acute Ethanol Dose
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison